Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer – a retrospective multi-centre study

Authors: Veronika Seebacher, Stephan Polterauer, Alexander Reinthaller, Heinz Koelbl, Regina Achleitner, Astrid Berger, Nicole Concin

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

AB0 blood groups and Rhesus factor expression have been associated with carcinogenesis, response to treatment and tumor progression in several malignancies. The aim of the present study was to test the hypothesis that AB0 blood groups and Rhesus factor expression are associated with clinical outcome in patients with epithelial ovarian cancer (EOC).

Methods

AB0 blood groups and Rhesus factor expression were evaluated in a retrospective multicenter study including 518 patients with EOC. Their association with patients’ survival was assessed using univariate and multivariable analyses.

Results

Neither AB0 blood groups nor Rhesus factor expression were associated with clinico-pathological parameters, recurrence-free, cancer-specific, or overall survival. In a subgroup of patients with high-grade serous adenocarcinoma, however, blood groups B and AB were associated with a better 5-year cancer-specific survival rate compared to blood groups A and 0 (60.3 ± 8.6% vs. 43.8 ± 3.6%, p = 0.04). Yet, this was not significant in multivariable analysis.

Conclusions

AB0 blood groups and Rhesus factor expression are both neither associated with features of biologically aggressive disease nor clinical outcome in patients with EOC. Further investigation of the role of the blood group B antigen on cancer-specific survival in the subgroup of high-grade serous should be considered.
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al (eds). SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD. [SEER Web site]. April 1, 2015. Available at: http://​seer.​cancer.​gov/​csr/​1975_​2012/​. Accessed 1 June 2016.
3.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mahters C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Globocan Web site]. 2013. Available at: http://​globocan.​iarc.​fr. Accessed 3 June 2016.
4.
Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, et al. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol. 2012;125:25–30.CrossRefPubMed
5.
Rubin SC, Finstad CL, Hoskins WJ, Provencher D, Federici MG, Lloyd KO, et al. Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:558–63.CrossRefPubMed
6.
7.
Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clément M. ABH and Lewis histo-blood group antigens in cancer. APMIS. 2001;109:9–31.CrossRefPubMed
8.
9.
Rhabari NN, Bork U, Hinz U, Leo A, Kirchberg J, Koch M, et al. AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 2012;12:319.CrossRef
10.
Klatte T, Xylinas E, Riecken M, Kluth LA, Rouprêt M, Pycha A, et al. Impact of AB0 blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. J Urol. 2014;191:1238–43.CrossRefPubMed
11.
Engel O, Soave A, Peine S, Kluth LA, Schmid M, Shariat SF, et al. The impact of the AB0 and the rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World J Urol. 2015;33:1769–76.CrossRefPubMed
12.
Zhang BL, He N, Huang YB, Song FJ, Chen KX. AB0 blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15:4643–50.CrossRefPubMed
13.
Gates MA, Wolpin BM, Cramer DW, Hankinson SE, Tworoger SS. AB0 blood group and incidence of epithelial ovarian cancer. Int J Cancer. 2011;128:482–6.CrossRefPubMed
14.
Marinaccio M, Traversa A, Carioggia E, Valentino L, Coviello M, Salamanna S, et al. Blood groups of the AB0 system and survival rate in gynecologic tumors. Minerva Ginecol. 1995;47:69–76.PubMed
15.
Zhou J, Yang LC, He ZY, Li FY, Wu SG, Sun JY. Prognostic impact of AB0 blood group on the survival in patients with ovarian cancer. J Cancer. 2015;6:970–5.CrossRefPubMedPubMedCentral
16.
Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology. Int J Gynaecol Obstet. 2000;70:209–2262.CrossRefPubMed
17.
Bethesda MD. Standards for blood banks and transfusion services. In: American Association of Blood Banks. 28th ed; 2012.
18.
Farhud DD, Zarif YM. A brief history of human blood groups. Iranian J Publ Health. 2013;42:1–6.
19.
Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.CrossRefPubMed
20.
Hakomori S. Antigen structure and genetic basis of histo-blood groups a, B and 0: their changes associated with human cancer. Biochim Biophys Acta. 1999;1473:247–66.CrossRefPubMed
21.
Cliby W, Ritland S, Hartman L, Dodson M, Halling KC, Keeney C, et al. Human epithelial ovarian cancer allelotype. Cancer Res. 1993;53:2393–8.PubMed
22.
Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, et al. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res. 1995;55:2150–7.PubMed
23.
Stapleton A, Nudelman E, Clausen H, Hakomori S, Stamm WE. Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status. J Clin Invest. 1992;90:965–72.CrossRefPubMedPubMedCentral
24.
Reid ME, Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol. 2004;41:93–117.CrossRefPubMed
25.
Ichikawa D, Handa K, Hakamori S. Histo- blood group a/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer. 1998;76:284–9.CrossRefPubMed
26.
Welshinger M, Finstad CL, Venkatraman E, Federici MG, Rubin SC, Lewis JL Jr, et al. Expression of a, B, and H blood group antigens in epithelial ovarian cancer: relationship to tumor grade and patient survival. Gynecol Oncol 1996;62:106–112.
27.
Huang CH, Ye M. The Rh protein family: gene evolution, membrane biology, and disease association. Cell Mol Life Sci. 2010;67:1203–18.CrossRefPubMed
28.
Metadata
Title
AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer – a retrospective multi-centre study
Authors
Veronika Seebacher
Stephan Polterauer
Alexander Reinthaller
Heinz Koelbl
Regina Achleitner
Astrid Berger
Nicole Concin
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4289-6

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Study protocol

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

Research article

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

Research article

Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients

Research article

The effect of low insurance reimbursement on quality of care for non-small cell lung cancer in China: a comprehensive study covering diagnosis, treatment, and outcomes

Research article

Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages

Research article

Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits